STOCKS TELEGRAPH

Tag: OPKO Health Inc.

  • OPKO Health, Inc. (OPK) Stock Dipping in Premarket Following Earnings Release

    OPKO Health, Inc. (OPK) Stock Dipping in Premarket Following Earnings Release

    OPKO Health, Inc. (OPK) is a global biotherapeutics and diagnostics company focused on the establishment of industry-leading positions in rapidly growing markets. The company leverages its marketing proficiency and innovative and exclusive technologies

    The price of OPK stock in regular trades on February 24, 2022, was $3.23 with an increase of 8.39%. The stock decelerated by 13.6% at the last check in the premarket on February 25, 2022,

    OPK: Key Financials

    On February 24, 2022, OPK released its financials for three months, and the fourth quarter ended December 31, 2021. Some of the crucial points are discussed below.

    Revenue

    Revenue in Q4 2021 was observed to be $401.3 million versus $494.6 million in the fourth quarter of 2020. The company observed a decrease of $93.3 million in revenue year-over-year.

    EPS

    Basic and diluted net loss in the fourth quarter of 2021 was $73.8 million or $0.11 per share versus a net income of $32.3 million, or $0.05 per share in the same period of 2020. The company observed a decline in its earnings over the year.

    OPK: Events and Happenings

    On February 15, 2022, OPK updated the grant of marketing approval for the NGENLA or somatrogon by the European Commission. It is used to treat children from 3 years of age with growth disorder due to inadequate growth hormone secretion. On February 03, 2022, OPK reported that Vifor Fresenius Medical Care Renal Pharma had begun the commercial-scale launch of RAYALDEE in Germany.

    On January 21, 2022, OPK announced the issuance of a Complete Response Letter by the FDA for the Biologics License Application for somatrogon. Pfizer assessed the agency’s comments and will work with it to determine a suitable path forward. On January 20, 2022, OPK and Pfizer Japan Inc. informed that NGENLA Injection 24 and 60 mg Pens, had been authorized by the Japanese Ministry of Health, Labor, and Welfare.

    On January 18, 2022, OPK and Sema4 updated on their entry into a definitive contract for Sema4 to purchase OPK’s subsidiary, GeneDx, Inc. On January 5, 2022, OPK reported its management’s presence at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022.

    Conclusion

    OPK stock is 26% down the past year. The company’s stock again declined in Friday’s premarket session as it announced its financials. The company’s financials observed a decline in its revenue and EPS over the year. For the upcoming quarter, the company’s revenue guidance is $317.2 million and EPS is -$0.02.

  • OPKO Health Inc. (OPK) stock Plummets Further After Hours on FDA’s CRL for Somatrogon

    OPKO Health Inc. (OPK) stock Plummets Further After Hours on FDA’s CRL for Somatrogon

    On January 21, OPKO Health Inc. (OPK) and Pfizer Inc. announced receiving a Complete Response Letter for somatrogon’s Biologics License Application. Consequently, OPK stock suffered a blow in the after-hours.

    During regular trading, the stock lost 2.75% at its closing price of $4.24 on Friday. Following the announcement, the stock plunged further to reach $3.75 in the after-hours. Hence, OPK lost a further 11.56% at an after-hours volume of 639K shares.

    The biopharmaceutical and diagnostics company, OPKO Health Inc. has a market capitalization of $2.89 billion. Currently, the company has 681.34 million shares outstanding in the market.

    Somatrogon

    Somatrogon is an investigational recombinant human growth hormone for the treatment of GHD (growth hormone deficiency) in pediatric patients. GHD is a rare disease in which the pituitary gland secretes an inadequate amount of the growth hormone. Thus causing a delay in puberty, restricted growth, and many other physical and associated mental problems as well.

    Previously, in 2014, OPK and Pfizer had entered into a worldwide agreement for developing and commercializing somatrogon for GHD. According to the agreement, clinical development is OPK’s responsibility while registration and commercialization are Pfizer’s.

    Recent Developments Regarding Somatrogon

    Pfizer has submitted regulatory applications for somatrogon to several countries around the world for review. Recently, NGENLA® (somatrogon) inj. Was approved by Japan’s Ministry of Health, Labor, and Welfare for treatment of growth failure in pediatric patients due to growth hormone. Moreover, in 2021, NGENLA® was also approved by Health Canada and Australia’s Therapeutic Goods Administration. Furthermore, a decision from European Commission is expected soon, based on EMA’s CHMP’s recent positive opinion.

    CRL regarding Somatrogon

    As per Friday’s announcement, FDA has issued a CRL for somatrogon’s Biologics License Application BLA). Currently, Pfizer is assessing the comments of the FDA and plans to work with the agency for the best course forward.

    OPK’s Recent Participation

    Recently, OPK participated in the 40th Annual J.P. Morgan Healthcare Conference which took place from January 10 to 13, 2022. Further, the company’s management hosted a one-on-one meeting with investors along with a fireside chat on January 12, at the conference.

    OPK’s Financial Data

    On October 28, the company declared its financial results for the third quarter of 2021.

    In the third quarter of 2021, consolidated total revenues reported were $385.8 million against $428.1 million in Q3 of 2020.

    Additionally, OPK ended the quarter with cash, cash equivalents, and marketable securities of $148.6 million.

  • 15 Trending Stocks To Watch In Diagnostics And Research Industry

    15 Trending Stocks To Watch In Diagnostics And Research Industry

    The Diagnostic Research Industry is playing an integral part in the medical evaluation and treatment of patients.  This industry is vital to the healthcare market as it is providing information related to the severity and causes of illnesses in patients to healthcare practitioners. The changes we are witnessing in today’s healthcare industry are setting the goal for evolution we will see over the next decade.

    There are major drivers that are changing and will change the direction of this industry in present and future as well. The first driver is technology. As time passes by, new technologies are emerging and playing a very important role in the healthcare industry. In today’s world, patients want easier access to care and demand better service. The demand for this industry is linked to the number of patients receiving the treatment. The profitability and growth of the company depend on good marketing and efficient operations.

    Let check these 15 companies in Diagnostic Research Industry to know more about this industry and the trends this industry is following:

    Interpace Biosciences Inc. (NASDAQ: IDXG)

    Interpace Biosciences Inc. (NASDAQ: IDXG) shares were trading up 32.89% at $3.96 at the time of writing on Wednesday. Interpace Biosciences Inc. (NASDAQ: IDXG) share price went from a low point around $2.57 to briefly over $11.00 in the past 52 weeks, though shares have since pulled back to $3.96. IDXG market cap has remained high, hitting $15.88M at the time of writing, giving it a price-to-sales ratio of more than 0.

    Interpace Biosciences Inc. (NASDAQ: IDXG) has announced that the Audit Committee has disclosed the result of an independent investigation. The committee has completed the investigation with the statement that the allegations made in the complaints were unverified and there is no truth behind them. investigation and If we look at the recent analyst rating IDXG, Janney initiated coverage on IDXG shares with a Buy rating.

    OPKO Health Inc. (NASDAQ: OPK)

    OPKO Health Inc. (NASDAQ: OPK) last closed at $4.07, in a 52-week range of $1.12 to $6.47. Analysts have a consensus price target of $8.00. OPKO Health Inc. (OPK) disclosed it plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020.

    Invitae Corporation (NYSE: NVTA)

    Invitae Corporation (NYSE: NVTA) stock drop by -6.29% to $49.28. The most recent rating by JP Morgan, on October 14, 2020, is at a Neutral. Invitae Corporation (NVTA) disclosed that on October 2, 2020, it has executed the transaction to bring ArcherDX into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization, and personalized cancer monitoring to enable precision approaches to cancer treatment.

    Pacific Biosciences of California Inc. (NASDAQ: PACB)

    Pacific Biosciences of California Inc. (NASDAQ: PACB) shares headed rising, higher as much as 0.07%. The most recent rating by JP Morgan, on October 02, 2020, is at an Overweight. Pacific Biosciences of California Inc. (PACB) has disclosed that collaborated with Children’s Mercy Kansas City to further understand the most challenging pediatric diseases. The companies will join forces to sequence a statistically significant cohort of rare disease cases for which previous whole-genome and whole-exome sequencing studies yielded no answers.

    Bionano Genomics Inc. (NASDAQ: BNGO)

    Bionano Genomics Inc. (NASDAQ: BNGO) fall -0.15% after losing more than $0.0 on Wednesday. Bionano Genomics Inc. (BNGO) revealed today that it is scheduled to release financial results of the third quarter ended September  30, 2020, on November 12, 2020. The company will also hold the conference call on the same day.

    T2 Biosystems Inc. (NASDAQ: TTOO)

    T2 Biosystems Inc. (NASDAQ: TTOO) stock drop by 0.00% to $1.33 after T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020. The most recent rating by BTIG Research, on October 08, 2020, is at a Buy.  T2 Biosystems Inc. (TTOO) market capitalization has remained high, hitting $196.79 million at the time of writing.

    NeoGenomics Inc. (NASDAQ: NEO)

    NeoGenomics Inc. (NASDAQ: NEO) Shares headed rising, higher as much as 5.46%. The most recent rating by Morgan Stanley, on September 09, 2020, is at an Overweight. NeoGenomics Inc. (NEO) revealed its plans to open a state-of-the-art research laboratory in China in association with the new lab PPD, Inc. (NASDAQ: PPD) is opening in Suzhou.

    PerkinElmer Inc. (NYSE: PKI)

    PerkinElmer Inc. (NYSE: PKI) fall -2.10% after losing more than -$2.62 on Wednesday. PerkinElmer Inc. (PKI) earlier announced that it is expected to report organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020.

    Chembio Diagnostics Inc. (NASDAQ: CEMI)

    Chembio Diagnostics Inc. (NASDAQ: CEMI) last closed at $4.77, in a 52-week range of $2.25 to $15.89. Analysts have a consensus price target of $5.00. Chembio Diagnostics Inc. (CEMI) disclosed earlier that the U.S. Food and Drug Administration (FDA) has approved the Premarket Approval (PMA) application for the DPP HIV-Syphilis System.

    Illumina Inc. (NASDAQ: ILMN)

    Illumina Inc. (NASDAQ: ILMN) Shares headed falling, lower as much as -4.35%. The most recent rating by Guggenheim, on October 13, 2020, is at a Neutral. Illumina Inc. (ILMN) has earlier announced that it is scheduled to release the third quarter 2020 following the close of the market on Thursday, October 29, 2020.

    Enzo Biochem Inc. (NYSE: ENZ)

    Enzo Biochem Inc. (NYSE: ENZ) fall -17.24% after losing more than -$0.45 on Wednesday. Enzo Biochem Inc. (ENZ) earlier reported financial results for the fourth quarter and full-year ended July 31, 2020, and provided a business update on recent corporate and operational developments.

    Fulgent Genetics Inc. (NASDAQ: FLGT)

    Fulgent Genetics Inc. (NASDAQ: FLGT) last closed at $38.17, in a 52-week range of $6.70 to $52.47. Analysts have a consensus price target of $56.25. Fulgent Genetics Inc. (FLGT) disclosed earlier that the Ohio Department of Rehabilitation and Correction (“ODRC”) has selected Fulgent Genetics for their COVID-19 testing needs.

    QIAGEN N.V. (NYSE: QGEN)

    QIAGEN N.V. (NYSE: QGEN) stock drop by -0.11% to $52.37. The most recent rating by BofA Securities, on October 06, 2020, is at a Buy. QIAGEN N.V. (QGEN) earlier announced preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020. It has shared that the Net sales grew 26% at actual rates, and also rose 26% at constant exchange rates (CER) $481.3 million from $382.7 million in the same period of 2019.

    Fluidigm Corporation (NASDAQ: FLDM)

    Fluidigm Corporation (NASDAQ: FLDM) last closed at $6.89, in a 52-week range of $1.17 to $12.45. Fluidigm Corporation (FLDM) has moved up 488.03% from its 52-weeks low and moved down -44.74% from its 52-weeks high. Looking at its liquidity, it has a current ratio of $509.65 million at the time of writing.

    Danaher Corporation (NYSE: DHR)

    Danaher Corporation (NYSE: DHR) stock soar by 0.41% to $226.55. The most recent rating by Wolfe Research, on June 16, 2020, is at an Outperform. Danaher Corporation (DHR) share price went from a low point around $119.60 to briefly over $227.48 in the past 52 weeks, though shares have since pulled back to $222.59. DHR  market cap has remained high, hitting $156.91 billion at the time of writing.

     

     

  • 10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

    10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

    Healthcare is a dynamic and opportunity-rich industry. The demand for innovations that brings improvement in health outcomes, affordability, quality, and access will continue to be high. The changes we witnessed in the healthcare industry today have set a new tone for the change in the coming few years. 2020 is the year of change for the health care industry.

    The first thing which played an important role in the healthcare industry is Technology. Technology is continuously changing and brings new improvement in the healthcare industry. Patients today want easier and affordable access to care and better demand services. In this changing environment, diagnostics is emerging as a key driver in helping to address these needs.

    Here are the top 10 leading companies in Diagnostics Research Industry that need your attention:

    OPKO Health Inc. (NASDAQ: OPK)

    OPKO Health Inc. (NASDAQ: OPK) shares were trading down -0.92% at $3.22 at the time of writing on Tuesday. OPKO Health Inc. (NASDAQ: OPK) share price went from a low point around $1.12 to briefly over $6.47 in the past 52 weeks, though shares have since pulled back to $3.22. OPK market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 2.

    OPKO Health Inc. has earlier started a Phase 2 trial with RAYALDEE as a treatment for mild-to-moderate COVID-19.  If we look at the recent analyst rating OPK, Piper Jaffray initiated coverage on OPK shares with an Overweight rating.

    Pacific Biosciences of California Inc. (NASDAQ: PACB)

    Pacific Biosciences of California Inc. (NASDAQ: PACB) last closed at $8.78, in a 52-week range of $2.20 to $8.38. Analysts have a consensus price target of $6.50. Pacific Biosciences of California Inc. (PACB) has announced it has appointed Susan G. Kim as Chief Financial Officer. The decision is effective as of September 28, 2020. Susan has joined the company at a time when there are various growth opportunities for the company.

    Bionano Genomics Inc. (NASDAQ: BNGO)

    Bionano Genomics Inc. (NASDAQ: BNGO) stock soar by 0.79% to $0.64. The most recent rating by Oppenheimer, on April 08, 2020, is at an Outperform. Bionano Genomics Inc. (BNGO) will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. the summit is scheduled to take place virtually on September 21-23, 2020. This company market capitalization has remained high, hitting $90.45 million at the time of writing.

    Illumina Inc. (NASDAQ: ILMN)

    Illumina Inc. (NASDAQ: ILMN) shares headed falling, lower as much as -0.60%. The most recent rating by UBS, on September 22, 2020, is at a Neutral. Illumina Inc. (ILMN) has officially revealed an agreement to buy cancer-testing company Grail for about $8 billion in cash and stock. This company market capitalization has remained high, hitting $39.54 billion at the time of writing.

    Precipio Inc. (NASDAQ: PRPO)

    Precipio Inc. (NASDAQ: PRPO) shares headed rising, higher as much as 2.63%. Precipio Inc. has revealed that it has introduced its HemeScreen AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering. This company market capitalization has remained high, hitting 37.42 million at the time of writing.

    Fulgent Genetics Inc. (NASDAQ: FLGT)

    Fulgent Genetics Inc. (NASDAQ: FLGT) stock soar by 7.08% to $40.25. The most recent rating by Oppenheimer, on August 20, 2020, is at an Outperform. Fulgent Genetics Inc. (FLGT) will replace Garrett Motion Inc. (GTX) in the S&P SmallCap 600 effective before the opening of trading on Friday, September 25. This company’s market capitalization has remained high, hitting $821.10 million at the time of writing.

    Fluidigm Corporation (NASDAQ: FLDM)

    Fluidigm Corporation (NASDAQ: FLDM) fall -1.29% after losing more than -$0.11 on Tuesday. In the past 52-weeks of trading, this company’s stock fluctuated between the low range of $1.17 and a high range of $12.45. It has moved up 595.73% from its 52-weeks low and moved down -34.62% from its 52-weeks high. Looking at its liquidity it has a current ratio of 2.00. This company’s market capitalization has remained high, hitting $523.91 million at the time of writing.

    Invitae Corporation (NYSE: NVTA)

    Invitae Corporation (NYSE: NVTA) last closed at $43.10, in a 52-week range of $7.41 to $40.96. Analysts have a consensus price target of $36.25. Invitae Corporation (NVTA) has moved up 475.19% from its 52-weeks low and moved down -2.16% from its 52-weeks high. Looking at its liquidity it has a current ratio of 3.70. This company’s market capitalization has remained high, hitting $5.56 billion at the time of writing.

    HTG Molecular Diagnostics Inc. (NASDAQ: HTGM)

    HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) fall -8.01% after losing more than -$0.03 on Tuesday. HTG Molecular Diagnostics Inc. (HTGM) share price went from a low point around $0.27 to briefly over $0.99 in the past 52 weeks, though shares have since pulled back to $0.32. HTG Molecular Diagnostics Inc. market cap has remained high, hitting $22.70 million at the time of writing

    Co-Diagnostics Inc. (NASDAQ: CODX)

    Co-Diagnostics Inc. (NASDAQ: CODX) last closed at $14.93, in a 52-week range of $0.85 to $30.99. Co-Diagnostics Inc. (CODX) has moved up 1567.08% from its 52-weeks low and moved down -54.47% from its 52-weeks high. Looking at its liquidity it has a current ratio of 11.60. This company’s market capitalization has remained high, hitting $404.90 million at the time of writing.